Currency in GBP
Last close As at 26/05/2023
GBP7.84
▲ 1.00 (0.13%)
Market capitalisation
GBP755m
Research: TMT
discoverIE’s trading update confirmed that performance in H122 was ahead of board expectations, with organic revenue growth of 15% y-o-y and 8% versus the pre-COVID H120. Despite supply chain challenges, the company maintained gross margins. Q222 order intake continued in the same strong vein as H221 and Q122, resulting in a record order book entering H222 and driving a small upgrade to our FY22 and FY23 forecasts.
discoverIE Group |
Starting H222 with a record order book |
H122 trading update |
Tech hardware & equipment |
18 October 2021 |
Share price performance
Business description
Next events
Analyst
discoverIE Group is a research client of Edison Investment Research Limited |
discoverIE’s trading update confirmed that performance in H122 was ahead of board expectations, with organic revenue growth of 15% y-o-y and 8% versus the pre-COVID H120. Despite supply chain challenges, the company maintained gross margins. Q222 order intake continued in the same strong vein as H221 and Q122, resulting in a record order book entering H222 and driving a small upgrade to our FY22 and FY23 forecasts.
Year end |
Revenue (£m) |
PBT* |
Diluted EPS* |
DPS |
P/E |
Yield |
03/20 |
466.4 |
34.6 |
31.8 |
3.0 |
33.8 |
0.3 |
03/21 |
454.3 |
32.6 |
27.0 |
10.2 |
39.9 |
0.9 |
03/22e |
529.6 |
40.3 |
31.2 |
10.7 |
34.5 |
1.0 |
03/23e |
556.0 |
44.2 |
33.2 |
11.0 |
32.5 |
1.0 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
H122 trading ahead of expectations
discoverIE noted that the strong order intake experienced in H221 and Q122 continued through Q222. H122 revenue was 23% higher y-o-y at constant exchange rates (CER), 15% higher y-o-y organically and 8% higher organically compared to H120 (pre-COVID). Orders grew 64% y-o-y on an organic basis and 34% compared to H120, with similar growth in both divisions. The order book at the end of H122 was 71% higher organically y-o-y and 53% higher than at the end of H120. Gross margins were maintained during H122 and the five acquisitions made over the last year are making excellent progress. Pro forma gearing (net debt/ adjusted EBITDA) at the end of H122 reduced to 1.4x from 1.6x at the end of FY21, below the company’s target range of 1.5–2.0x providing headroom for further acquisitions.
Small upgrade to estimates
Management noted that performance in H122 was ahead of board expectations, despite currency headwinds and supply chain challenges. While the company reported that supply chain issues limited revenue growth slightly in H122, we estimate that growth was ahead of our forecast. We have revised up our FY22 and FY23 revenue estimates by 1.1% and underlying EPS by 1.3% in both years. The strong order book at the end of H122 provides good visibility for H222, with the ability to ship product the limiting factor for growth, rather than any lack of customer demand.
Valuation: Reflects growth potential
On our revised forecasts, the stock trades towards the upper end of its peer group on a P/E basis, in our view reflecting the group’s potential to drive earnings growth through accretive acquisitions. Aside from the ongoing recovery in customer demand, we view the key trigger for earnings and share price upside to be progress in increasing the weighting of the business towards the higher-growth, higher-margin D&M business (organically and via acquisition), which in turn should move the company closer to its 12.5% medium-term operating margin target.
Changes to forecasts
Exhibit 1: Changes to estimates
£m |
FY22e old |
FY22e new |
Change |
y-o-y |
FY23e old |
FY23e new |
Change |
y-o-y |
Revenues |
523.8 |
529.6 |
1.1% |
16.6% |
550.0 |
556.0 |
1.1% |
5.0% |
Design & manufacturing |
354.0 |
358.2 |
1.2% |
20.8% |
375.9 |
380.2 |
1.1% |
6.1% |
Custom supply |
169.8 |
171.4 |
0.9% |
8.7% |
174.1 |
175.8 |
1.0% |
2.6% |
Gross margin |
33.9% |
33.9% |
(0.0%) |
(0.3%) |
33.9% |
33.9% |
0.0% |
0.0% |
EBITDA |
57.3 |
57.8 |
0.9% |
19.3% |
62.4 |
62.9 |
0.9% |
9.0% |
EBITDA margin |
10.9% |
10.9% |
(0.0%) |
0.3% |
11.3% |
11.3% |
(0.0%) |
0.4% |
Underlying operating profit |
42.8 |
43.3 |
1.1% |
22.9% |
47.4 |
47.9 |
1.1% |
10.8% |
Underlying operating margin |
8.2% |
8.2% |
0.0% |
0.4% |
8.6% |
8.6% |
0.0% |
0.5% |
Normalised operating profit |
44.6 |
45.1 |
1.1% |
24.1% |
49.2 |
49.7 |
1.1% |
10.4% |
Normalised operating margin |
8.5% |
8.5% |
(0.0%) |
0.5% |
8.9% |
8.9% |
0.0% |
0.4% |
Normalised PBT |
39.8 |
40.3 |
1.2% |
23.6% |
43.6 |
44.2 |
1.2% |
9.6% |
Normalised net income |
29.5 |
29.9 |
1.2% |
20.0% |
32.1 |
32.5 |
1.2% |
8.8% |
Normalised diluted EPS (p) |
30.8 |
31.2 |
1.2% |
15.6% |
32.7 |
33.2 |
1.2% |
6.3% |
Underlying diluted EPS (p) |
29.4 |
29.8 |
1.3% |
14.5% |
31.4 |
31.8 |
1.3% |
6.8% |
Reported basic EPS (p) |
17.8 |
18.2 |
2.2% |
34.7% |
20.6 |
21.0 |
2.0% |
15.4% |
Dividend per share (p) |
10.7 |
10.7 |
0.0% |
5.4% |
11.0 |
11.0 |
0.0% |
2.8% |
Net (debt)/cash |
(82.1) |
(78.2) |
(4.8%) |
65.7% |
(72.1) |
(70.6) |
(2.1%) |
(9.7%) |
Net debt/EBITDA (x) |
1.5 |
1.4 |
1.3 |
1.3 |
Source: Edison Investment Research
Exhibit 2: Financial summary
£m |
2018 |
2019 |
2020 |
2021 |
2022e |
2023e |
||
Year end 31 March |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||||
Revenue |
|
|
387.9 |
438.9 |
466.4 |
454.3 |
529.6 |
556.0 |
Cost of Sales |
(261.2) |
(293.9) |
(309.7) |
(299.0) |
(350.3) |
(367.5) |
||
Gross Profit |
126.7 |
145.0 |
156.7 |
155.3 |
179.3 |
188.5 |
||
EBITDA |
|
|
29.3 |
37.0 |
50.9 |
48.4 |
57.8 |
62.9 |
Operating Profit (before am, SBP and except.) |
|
25.2 |
31.8 |
38.9 |
36.3 |
45.1 |
49.7 |
|
Operating Profit (before am. and except.) |
|
24.5 |
30.6 |
37.1 |
35.2 |
43.3 |
47.9 |
|
Amortisation of acquired intangibles |
(4.9) |
(5.9) |
(9.0) |
(11.1) |
(11.6) |
(11.6) |
||
Exceptionals |
(2.3) |
(2.0) |
(4.3) |
(3.4) |
(4.0) |
(3.6) |
||
Share-based payments |
(0.7) |
(1.2) |
(1.8) |
(1.1) |
(1.8) |
(1.8) |
||
Operating Profit |
17.3 |
22.7 |
23.8 |
20.7 |
27.7 |
32.7 |
||
Net Interest |
(2.6) |
(3.4) |
(4.3) |
(3.7) |
(4.8) |
(5.6) |
||
Profit Before Tax (norm) |
|
|
22.6 |
28.4 |
34.6 |
32.6 |
40.3 |
44.2 |
Profit Before Tax (FRS 3) |
|
|
14.6 |
19.3 |
19.5 |
17.0 |
22.8 |
27.1 |
Tax |
(4.0) |
(4.7) |
(5.2) |
(5.0) |
(5.9) |
(7.1) |
||
Profit After Tax (norm) |
17.1 |
21.5 |
27.6 |
24.9 |
29.9 |
32.5 |
||
Profit After Tax (FRS 3) |
10.6 |
14.6 |
14.3 |
12.0 |
16.9 |
19.9 |
||
Ave. Number of Shares Outstanding (m) |
70.8 |
73.0 |
84.0 |
88.8 |
92.6 |
94.8 |
||
EPS - normalised & diluted (p) |
|
|
23.0 |
28.4 |
31.8 |
27.0 |
31.2 |
33.2 |
EPS - underlying, diluted (p) |
|
|
22.3 |
27.2 |
30.2 |
26.0 |
29.8 |
31.8 |
EPS - IFRS basic (p) |
|
|
15.0 |
20.0 |
17.0 |
13.5 |
18.2 |
21.0 |
EPS - IFRS diluted (p) |
|
|
14.2 |
19.4 |
16.5 |
13.0 |
17.6 |
20.3 |
Dividend per share (p) |
9.0 |
9.6 |
3.0 |
10.2 |
10.7 |
11.0 |
||
Gross Margin (%) |
32.7 |
33.0 |
33.6 |
34.2 |
33.9 |
33.9 |
||
EBITDA Margin (%) |
7.6 |
8.4 |
10.9 |
10.7 |
10.9 |
11.3 |
||
Operating Margin (before am, SBP and except.) (%) |
6.5 |
7.2 |
8.3 |
8.0 |
8.5 |
8.9 |
||
discoverIE adjusted operating margin (%) |
6.3 |
7.0 |
8.0 |
7.7 |
8.2 |
8.6 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
136.4 |
149.2 |
236.4 |
245.0 |
320.2 |
309.9 |
Intangible Assets |
107.2 |
119.7 |
182.2 |
191.2 |
265.0 |
253.8 |
||
Tangible Assets |
23.4 |
24.4 |
46.3 |
45.9 |
47.3 |
48.2 |
||
Deferred tax assets |
5.8 |
5.1 |
7.9 |
7.9 |
7.9 |
7.9 |
||
Current Assets |
|
|
165.9 |
179.1 |
197.4 |
183.6 |
174.6 |
187.7 |
Stocks |
58.1 |
66.2 |
68.4 |
67.7 |
79.5 |
83.5 |
||
Debtors |
84.6 |
88.7 |
90.1 |
84.9 |
100.1 |
106.6 |
||
Cash |
21.9 |
22.9 |
36.8 |
29.2 |
(6.8) |
(4.2) |
||
Current Liabilities |
|
|
(94.0) |
(96.0) |
(103.6) |
(107.8) |
(124.4) |
(128.5) |
Creditors |
(87.6) |
(94.3) |
(94.0) |
(102.2) |
(118.8) |
(122.9) |
||
Lease liabilities |
0.0 |
0.0 |
(5.3) |
(4.8) |
(4.8) |
(4.8) |
||
Short term borrowings |
(6.4) |
(1.7) |
(4.3) |
(0.8) |
(0.8) |
(0.8) |
||
Long Term Liabilities |
|
|
(81.5) |
(97.6) |
(129.7) |
(112.0) |
(98.9) |
(85.8) |
Long term borrowings |
(67.9) |
(84.5) |
(93.8) |
(75.6) |
(70.6) |
(65.6) |
||
Lease liabilities |
0.0 |
0.0 |
(14.7) |
(16.7) |
(16.1) |
(15.5) |
||
Other long term liabilities |
(13.6) |
(13.1) |
(21.2) |
(19.7) |
(12.2) |
(4.7) |
||
Net Assets |
|
|
126.8 |
134.7 |
200.5 |
208.8 |
271.6 |
283.3 |
CASH FLOW |
||||||||
Operating Cash Flow |
|
|
21.7 |
30.0 |
48.0 |
57.2 |
44.9 |
54.6 |
Net Interest |
(2.6) |
(3.4) |
(3.7) |
(3.1) |
(4.2) |
(5.0) |
||
Tax |
(3.7) |
(3.8) |
(6.4) |
(7.2) |
(10.4) |
(11.7) |
||
Capex |
(4.3) |
(5.4) |
(6.3) |
(3.9) |
(8.5) |
(8.5) |
||
Acquisitions/disposals |
(25.4) |
(22.4) |
(73.6) |
(20.5) |
(90.1) |
(5.0) |
||
Financing |
(1.5) |
0.1 |
53.9 |
(6.6) |
46.7 |
(6.7) |
||
Dividends |
(6.2) |
(6.7) |
(8.1) |
(2.8) |
(9.5) |
(10.1) |
||
Net Cash Flow |
(22.0) |
(11.6) |
3.8 |
13.1 |
(31.0) |
7.6 |
||
Opening net cash/(debt) |
|
|
(30.0) |
(52.4) |
(63.3) |
(61.3) |
(47.2) |
(78.2) |
HP finance leases initiated |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other |
(0.4) |
0.7 |
(1.8) |
1.0 |
(0.0) |
(0.0) |
||
Closing net cash/(debt) |
|
|
(52.4) |
(63.3) |
(61.3) |
(47.2) |
(78.2) |
(70.6) |
Source: discoverIE, Edison Investment Research
|
|
Research: Industrials
Thrace continued to successfully service high medical sector demand and support customers elsewhere in the face of input cost pressures in H121. Cash generation has boosted balance sheet strength and Thrace plans to increase capex to enhance business capabilities and its sustainability credentials. With more normal trading (ie sharply lower medical sector demand) factored in for FY22 and beyond – including slightly raised estimates – the valuation does not look stretched and the outlook for cash generation should present further opportunities to enhance returns.
Get access to the very latest content matched to your personal investment style.